---
title: "Urogen Pharma General Counsel Jason Drew Smith Disposes of Common Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275651690.md"
datetime: "2026-02-11T19:55:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275651690.md)
  - [en](https://longbridge.com/en/news/275651690.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275651690.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275651690.md) | [繁體中文](https://longbridge.com/zh-HK/news/275651690.md)


# Urogen Pharma General Counsel Jason Drew Smith Disposes of Common Shares

Jason Drew Smith, General Counsel of Urogen Pharma Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-003778), on February 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [UroGen Pharma Ltd. (URGN.US)](https://longbridge.com/en/quote/URGN.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/en/news/278542482.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/en/news/278380208.md)
- [Vertex's kidney disease drug meets main goal in late-stage trial](https://longbridge.com/en/news/278442392.md)